| __timestamp | Amneal Pharmaceuticals, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 84615000 | 1860000 |
| Thursday, January 1, 2015 | 109679000 | 2963000 |
| Friday, January 1, 2016 | 118757000 | 6961000 |
| Sunday, January 1, 2017 | 109046000 | 11779000 |
| Monday, January 1, 2018 | 230435000 | 13697000 |
| Tuesday, January 1, 2019 | 289598000 | 15749000 |
| Wednesday, January 1, 2020 | 326727000 | 18638000 |
| Friday, January 1, 2021 | 365504000 | 27196000 |
| Saturday, January 1, 2022 | 399700000 | 31739000 |
| Sunday, January 1, 2023 | 429675000 | 33491000 |
Infusing magic into the data realm
In the competitive landscape of pharmaceuticals, operational efficiency is key. Amneal Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. Over the past decade, Amneal has seen a steady increase in SG&A costs, rising from approximately $85 million in 2014 to over $430 million in 2023. This represents a staggering 400% increase, reflecting their aggressive expansion and market penetration strategies.
Conversely, Protagonist Therapeutics, Inc. has maintained a more conservative growth trajectory. Their SG&A expenses grew from around $1.9 million in 2014 to $33 million in 2023, marking a 17-fold increase. This growth, while significant, is indicative of a more measured approach to scaling operations. As these companies continue to evolve, their SG&A strategies will be pivotal in shaping their future success.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Protagonist Therapeutics, Inc.
Breaking Down SG&A Expenses: Sanofi vs Amneal Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Insmed Incorporated or Amneal Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Amneal Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Amneal Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.
Amneal Pharmaceuticals, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Operational Costs Compared: SG&A Analysis of Amneal Pharmaceuticals, Inc. and PTC Therapeutics, Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Soleno Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amneal Pharmaceuticals, Inc. and MiMedx Group, Inc.